Here are three findings:
1. In 2013, the market was valued at $1.8 billion.
2. North America dominates the global spinal biologics market, with the U.S. leading the pack.
3. Key companies in the market include DePuy Synthes, NuVasive and Orthofix International.
More articles on biologics:
Anika Therapeutics resumes distribution of cartilage regeneration treatments
AlloSource earns laser etching patent: 3 notes
4 things to know about Bio2 Technologies
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
